NCT04590612

Improving Quality of Life in Early Parkinson's Disease

The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Western University, Canada · Academic / Other
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The study will examine 30 patients between ages 50-80, newly diagnosed with early-stage Parkinson's Disease. Patients will be randomized to receive either Citalopram or Carbidopa-levodopa. The investigators' primary outcome measure will be change in quality of life over a prospective period of 6 months. Secondary outcome measures will include change in mood state and motor symptoms, as well as comparison of improvement between two treatments. Primary investigators would also like to collect quantitative electroencephalogram (qEEG) recordings, which is a reading of brain activity as an additional interest of this study. Primary investigators will assess the qEEG recordings for electrophysiological findings before and after interventions.

Conditions

• Parkinson Disease
• Depression

Interventions

Type	Name	Description
DRUG	Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet	25mg-100mg tablets to be taken orally three times a day on an empty stomach
DRUG	Citalopram	20 mg tablet to be taken orally once and at the same time of the day, daily.

Timeline

• Start date: 2021-01-01
• Primary completion: 2022-01-01
• Completion: 2022-01-01
• First posted: 2020-10-19
• Last updated: 2020-10-19